Ortho-McNeil: A Doctor Joined the Topamax Sales Call

In the Ortho-McNeil Topamax fraud settlement, Ortho-McNeil-Janssen Pharmaceuticals Inc. agreed to pay $75.37 million to resolve allegations that off-label psychiatric promotion caused false claims to Medicaid and other government health care programs. The government alleged that Ortho-McNeil Pharmaceutical’s Doctor-for-a-Day program put outside physicians alongside sales representatives in provider offices and at promotional meetings and dinners. Taxpayers allegedly paid for psychiatric prescriptions the programs did not cover.

The Department of Justice announced the resolution on April 29, 2010. This pharmaceutical fraud case connects a recognizable sales arrangement to the prescriptions and government payments the campaign allegedly generated. Its name sounded like a brief visit from a doctor. The government described a company-organized way to promote Topamax for psychiatric uses.

A Physician on the Sales Call

The government described Doctor-for-a-Day as a program that used physicians in the sales effort. Ortho-McNeil Pharmaceutical allegedly hired outside doctors to accompany its representatives on visits to healthcare providers and to speak about prescribing Topamax for unapproved uses and doses.

That arrangement matters because of where it placed the physician: in the customer’s office with a sales representative, or speaking at a promotional event. A sales or medical employee would recognize the different parts of that work: arranging the visit, bringing in the physician, preparing the discussion and deciding which use of the drug to promote. Each is a place to examine who directed the campaign and what the participants were expected to accomplish.

The physician’s presence is the striking part of the allegation. Ortho-McNeil was allegedly buying a doctor’s participation in selling the drug to other healthcare providers. The outside doctor became part of the pitch.

The same attention to actual work matters in physician consulting arrangements. What did the company hire the physician to do, and what happened during the engagement? In Topamax, the government’s description supplies a concrete answer: office visits with sales staff and talks promoting unapproved prescribing. That is the conduct to follow through the campaign’s materials and decisions.

What Is Considered Off-Label Promotion?

Off-label promotion markets a drug for a use outside its FDA approval. In the Topamax case, the government described promotion for psychiatric uses and unapproved doses. Its announcement identified Topamax’s approval for partial-onset seizures and said the FDA had not approved it for any psychiatric use.

The civil allegation then followed the promotion into reimbursement. The government alleged that the campaign caused claims for psychiatric uses that were not medically accepted indications and therefore were not covered by the government programs billed. That is the central connection in off-label promotion and pharmaceutical false claims: the message, the use it encouraged and the public money paid for that use.

A manufacturer can cause a false claim even when a pharmacy or physician submits the bill. The person making the sales presentation and the person submitting the reimbursement claim can sit in different businesses. Following the transaction connects them.

For an insider, that means the sales message and the payment records answer different parts of the case. The presentation can show which use the company encouraged. The prescribing and reimbursement information can show whether that use reached a government-funded claim. We examine that connection with the people who know how the campaign worked, including what the sales team was told to emphasize and how the resulting prescriptions were paid.

Why the Treatment Use Matters

The condition being treated can matter to coverage even when the drug is the same. A 2018 article in Managed Care, Indication-Specific Drug Pricing–Simple in Theory, Complex in Reality, explains that payers may cover a drug for one indication and decline coverage for another. An interview in the article describes the practical information gap:

That observation helps explain why the Topamax allegation needs more than a drug name on a claim. The government’s account turns on the psychiatric use for which the prescription was generated. We would examine how the promoted use, the clinical record and the reimbursement information fit together. A sales employee may know what was said in the office, while someone working with claims may see a different part of the same transaction.

The Company Behind the Civil Payment

Ortho-McNeil-Janssen Pharmaceuticals Inc. agreed to make the civil payment. The government identified it and Ortho-McNeil Pharmaceutical LLC as Johnson & Johnson subsidiaries, and described Ortho-McNeil Pharmaceutical as operating the Doctor-for-a-Day promotion.

Of the civil settlement, $24,681,516 was allocated to state Medicaid programs. The state allocation makes the public-payment consequence tangible: the alleged psychiatric sales campaign reached a program jointly funded by federal and state governments.

Ortho-McNeil-Janssen also agreed to a corporate integrity agreement with the Department of Health and Human Services Office of Inspector General, with procedures and reviews to prevent and promptly detect similar conduct.

For a compliance employee, the physician’s assignment, the uses discussed and the company’s review of that work are where we would examine whether the practice matched the policy.

What Is an Example of a Pharmaceutical Whistleblower Case?

The Topamax resolution is an example of a pharmaceutical whistleblower case built around a company’s promotional conduct and the government claims it allegedly caused. It resolved two qui tam lawsuits filed in the District of Massachusetts under the False Claims Act.

The government’s announcement credits the cases to private citizens using the law’s whistleblower provisions. That origin matters to someone who knows the sales operation from inside: the civil case can begin with knowledge of the company’s conduct, then connect that conduct to public payments. The Doctor-for-a-Day arrangement gives that knowledge a specific subject, a physician participating in a campaign to sell unapproved psychiatric uses.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the Topamax resolution, the Justice Department announced that the whistleblowers would receive more than $9 million collectively from the federal share of the civil recovery.

What an Insider Would Recognize

A promotion case connects what the company planned, what its representatives said and what its records preserved. The Topamax announcement identifies a physician-accompaniment program, office visits, meetings, dinners, and messages about unapproved uses and doses. Those are concrete activities an employee can describe.

We look at the campaign’s records together with the insider’s account of the work. Two other pharmaceutical complaints show why the written record and the conversation can differ.

The Discussion Missing From the Call Notes

In a whistleblower’s complaint against Abbott Laboratories, the allegation concerned what representatives were told to leave out after meeting doctors:

The complaint also alleged that Abbott trained representatives to encourage TriCor use with statins through scripts that omitted the combination’s risks. Read together, those allegations concern both the message delivered and the account left behind. The employee who heard the training may explain something the completed call note leaves out.

A Question Prepared in Advance

Another complaint, against Amgen, alleged that representatives used a non-branded piece about a disease to draw out an apparently unsolicited question about using Aranesp. The representatives would then use prepared data to promote the off-label use.

That allegation concerns who started the conversation and how it was arranged. A question from the customer could be the intended result of the representative’s presentation. Someone familiar with the training could explain how the discussion was designed before the visit began.

The complaints illustrate why we examine both the campaign’s instructions and the employee’s account of what happened in the room. For a physician-accompaniment program like Doctor-for-a-Day, the doctor’s actual role matters: what the company asked the physician to discuss and how that discussion served the sales effort.

A Separate Ortho-McNeil Medicaid Rebate Case

Ortho-McNeil Pharmaceutical also paid $3.4 million in a separate Dermatop rebate settlement that the Justice Department announced on October 19, 2009. That matter concerned drug classification for Medicaid rebates.

The government alleged that the companies in that resolution sold innovator drugs made by other manufacturers but reported them as non-innovator drugs, reducing the rebates they paid. Participating manufacturers pay quarterly rebates to Medicaid, and the announcement explained that innovator drugs carried a higher rebate than non-innovator drugs.

The Dermatop transaction belongs with the rebate reports and the money owed back to Medicaid. The Topamax transaction belongs with the promotional program and the claims it allegedly generated. An employee’s knowledge of either can be valuable, but the drug, the business decision and the payment obligation tell different stories.

You Know What the Doctor Was Asked to Sell

If you worked on physician visits, promotional meetings or the claims that followed, speak to one of our whistleblower experts about the campaign you saw. We connect your knowledge of the sales operation to the government-payment case and bring in pharmaceutical fraud whistleblower lawyers who understand promotion and reimbursement. We stay beside you as partners, using your knowledge of the physician’s role and the company’s decisions to build your strongest pharmaceutical whistleblower case.